Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
SUPPLEMENTARY METHODS

Definition of borderline resectable pancreatic cancer (BRPC) according to the NCCN resectability criteria
According to the NCCN resectability criteria, tumors considered BRPC include the following: (1) venous contact with the superior mesenteric vein (SMV) or portal vein (PV) of greater than 180°, contact of 180° or lesser with contour irregularity of the vein or thrombosis of the vein but with suitable vessel proximal and distal to the site of involvement allowing for safe and complete resection and vein reconstruction, contact with the inferior vena cava; (2) arterial contact with common hepatic artery (CHA) without extension to celiac axis or hepatic artery bifurcation allowing for safe and complete resection and reconstruction, solid tumor contact with the superior mesenteric artery of 180° or lesser or presence of variant arterial anatomy (ex: accessory right hepatic artery, replaced right hepatic artery, replaced CHA and the origin of replaced or accessory artery) and the presence and degree of tumor contact should be noted if present as it may after surgical planning for pancreatic head/uncinate process cancer; and (3) arterial contact with the celiac axis (CA) of 180° or lesser or contact with the CA of greater than 180° without involvement of the aorta and with intact
